Dublin, Dec. 01, 2021 (GLOBE NEWSWIRE) -- The "Automated and Closed Cell Therapy Processing Systems Market Size, Share & Trends Analysis Report by Workflow (Separation, Expansion), by Type (Non-stem Cell, Stem Cell), by Scale, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
The global automated and closed cell therapy processing systems market is expected to reach USD 2.94 billion by 2028, registering a CAGR of 21.7% over the forecast period. Market players are making significant investments to introduce an automated process system as a viable strategy to accelerate their cell therapy product development process, thereby driving market growth.
The expansion of GMP manufacturing facilities further supports the implementation of automated processes for commercial operations. In addition, the wide application scope of single-use disposable tubing sets and bags also facilitates automated processing of therapy R&D. Moreover, key entities are undertaking strategies for effective implementation of automation technology in manufacturing labs resulting in lucrative revenue growth.
The rapid growth in the cases of COVID-19 is anticipated to play a vital role in the market growth. The pandemic has led to an increased focus on automation technologies. Moreover, the companies emphasized raising funds with an aim to develop advanced therapies and regenerative medicines to fight against COVID-19. Industry players are also concentrating on the development of new therapies, such as stem cell therapy, natural killer cell therapy, exosomes, and others.
Automated And Closed Cell Therapy Processing Systems Market Report Highlights
- The cell expansion workflow segment accounted for the maximum revenue share of the global market in 2020. An increasing focus on achieving high output yield has resulted in the high revenue share of the segment
- The cell separation workflow segment is estimated to register the fastest CAGR during the forecast period due to an increasing number of stem cell therapy R&D programs
- Automated apheresis and cryopreservation workflow are also expected to register considerable growth rates over the forecast period due to the growing emphasis on preservation and sorting for cell therapies
- The non-stem cellular therapies segment dominated the market in 2020 and will expand further at a steady CAGR over the forecast period. The success of CAR T therapies is one of the major driving forces of this segment
- The pre-commercial/R&D scale segment captured the maximum revenue share in 2020 due to the increased number of research and innovation activities for new drug & therapy developments
- North America emerged as the highest revenue-generating region in 2020 owing to the presence of a large number of approved therapies in the region influencing the market players to invest in more R&D programs
- Companies are undertaking strategic initiatives, such as partnerships and collaborations, to gain higher market shares. For instance, in January 2021, Fresenius Kabiformed a joint venture with Bio-Techne to launch ScaleReady, to develop a scalable and versatile therapy manufacturing platform
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends & Scope
Chapter 4. Industry Outlook
4.1 Parent Market Lineage
4.2 Ancillary Market Lineage
4.3 Market Dynamics
4.3.1 Market Driver Analysis
4.3.1.1 Rising Emphasis on Regenerative Medicines and Cell Therapies
4.3.1.2 Operational Superiority of Automated Systems Over Manual Processing
4.3.1.3 Extensively Increasing Technological Advancements
4.3.2 Market Restraint Analysis
4.3.2.1 Biological Variations Associated with Different Therapies
4.3.3 Market Opportunity Analysis
4.3.3.1 Growing Fund-Raising Activities by Companies for New Technology Development
4.3.3.2 Research Activitis and Product Innovations
4.3.4 Market Challenge Analysis
4.3.4.1 Complicated Process of Automation
4.4 SWOT Analysis; by Factor (Political & Legal, Economic and Technological)
4.5 Porter's Five Forces Analysis
4.6 Major Deals and Strategic Alliances Analysis
4.6.1 Mergers and Acquisitions
4.6.2 Technological Collaborations and Partnerships
4.6.3 Product Approvals and Launches
4.7 COVID-19 Impact Analysis
4.7.1 Challenge Analysis
4.7.2 Opportunity Analysis
4.7.3 Key Developments and Activities
Chapter 5. Competitive Analysis
5.1 Company Mapping
5.2 List of Potential End-users
5.3 List of Emerging Players
5.4 Market Differentiators
5.5 Competitive Dashboard Analysis
5.6 Regional Network Map
Chapter 6. Workflow Business Analysis
6.1 Automated and Closed Cell Therapy Processing Systems Market: Workflow Movement Analysis
6.2 Separation
6.2.1 Separation Market Estimates and Forecast, 2017 - 2028 (USD Million)
6.3 Expansion
6.3.1 Expansion Market Estimates and Forecast, 2017 - 2028 (USD Million)
6.4 Apheresis
6.4.1 Apheresis Market Estimates and Forecast, 2017 - 2028 (USD Million)
6.5 Fill-Finish
6.5.1 Fill-Finish Market Estimates and Forecast, 2017 - 2028 (USD Million)
6.6 Cryopreservation
6.6.1 Cryopreservation Market Estimates and Forecast, 2017 - 2028 (USD Million)
6.7 Others
6.7.1 Others Market Estimates and Forecast, 2017 - 2028 (USD Million)
Chapter 7. Type Business Analysis
7.1 Automated and Closed Cell Therapy Processing Systems Market: Type Movement Analysis
7.2 Stem Cell Therapy
7.2.1 Stem Cell Therapy Market Estimates and Forecast, 2017 - 2028 (USD Million)
7.3 Non-Stem Cell Therapy
7.3.1 Non-Stem Cell Therapy Market Estimates and Forecast, 2017 - 2028 (USD Million)
Chapter 8. Scale Business Analysis
8.1 Automated and Closed Cell Therapy Processing Systems Market: Scale Movement Analysis
8.2 Pre-Commercial/R&D Scale Manufacturing
8.2.1 Pre-Commercial/R&D Scale Manufacturing Market Estimates and Forecast, 2017 - 2028 (USD Million)
8.3 Commercial Scale Manufacturing
8.3.1 Commercial Scale Manufacturing Market Estimates and Forecast, 2017 - 2028 (USD Million)
Chapter 9. Regional Business Analysis
Chapter 10 Company Profiles
10.1 Strategy Framework
10.2 Market Participation Categorization
10.3 Company Profiles
10.3.1 Miltenyi Biotec
10.3.1.1 Company Overview
10.3.1.2 Product Benchmarking
10.3.1.3 Strategic Initiatives
10.3.2 Lonza
10.3.2.1 Company Overview
10.3.2.2 Financial Performance
10.3.2.3 Product Benchmarking
10.3.2.4 Strategic Initiatives
10.3.3 Fresenius Kabi
10.3.3.1 Company Overview
10.3.3.2 Financial Performance
10.3.3.3 Product Benchmarking
10.3.3.4 Strategic Initiatives
10.3.4 Cytiva (Danaher Corporation)
10.3.4.1 Company Overview
10.3.4.2 Financial Performance
10.3.4.3 Product Benchmarking
10.3.4.4 Strategic Initiatives
10.3.5 Biospherix, Ltd.
10.3.5.1 Company Overview
10.3.5.2 Product Benchmarking
10.3.5.3 Strategic Initiatives
10.3.6 Terumo Corporation
10.3.6.1 Company Overview
10.3.6.2 Financial Performance
10.3.6.3 Product Benchmarking
10.3.6.4 Strategic Initiatives
10.3.7 Sartorius Ag
10.3.7.1 Company Overview
10.3.7.2 Financial Performance
10.3.7.3 Product Benchmarking
10.3.7.4 Strategic Initiatives
10.3.8 Thermogenesis Holdings, Inc.
10.3.8.1 Company Overview
10.3.8.2 Financial Performance
10.3.8.3 Product Benchmarking
10.3.8.4 Strategic Initiatives
10.3.9 Cellares Inc.
10.3.9.1 Company Overview
10.3.9.2 Product Benchmarking
10.3.9.3 Strategic Initiatives
10.3.10 Thermo Fisher Scientific, Inc.
10.3.10.1 Company Overview
10.3.10.2 Financial Performance
10.3.10.3 Product Benchmarking
10.3.10.4 Strategic Initiatives
For more information about this report visit https://www.researchandmarkets.com/r/37umbb
